newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen® in multiple high-value indications - Company expected to continue advancing oncology-focused p